Wild Type
Wild Type is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Wild Type.
Wild Type is a company.
Key people at Wild Type.
Key people at Wild Type.
Wildtype is a San Francisco-based startup producing cultivated (cell-based) salmon to provide sustainable, clean seafood without relying on wild-caught or farmed fish. The company grows salmon cells in bioreactors, delivering buttery-textured, umami-rich salmon free from contaminants like mercury, parasites, antibiotics, and microplastics, while preserving nutrients such as omega-3s[1][2][6]. It serves consumers, chefs, and the food industry, addressing overfishing, unsustainable aquaculture, and rising global seafood demand amid population growth and ocean degradation[1][2][3]. Wildtype has raised over $120 million, including a $100 million Series B, employs around 60 people, and achieved a milestone as the first cultivated seafood cleared for U.S. sale by the FDA in early 2025, debuting at restaurants like Kann in Portland[5][6][7].
Wildtype was founded in 2016 by Aryé Elfenbein, a cardiologist and microbiologist, and Justin Kolbeck, a former diplomat, driven by concerns over unsustainable seafood production[3][5]. The idea emerged from recognizing seafood demand's collision with depleting wild stocks—one-third of marine fish stocks are overfished—and harmful farming practices; they pivoted from an initial idea (a redesigned Neti pot called "The Schnozel") to cellular agriculture for fish[1][2][5]. Early efforts involved a year of R&D to produce edible salmon, followed by transparent chef feedback sessions with hundreds in the industry to refine taste and viability, prioritizing culinary development via crowdsourcing rather than an internal chef[4]. Pivotal moments include raising $3.5 million initially, a $100 million Series B, and FDA clearance in 2025 after submitting safety data in 2022[3][4][6].
Wildtype rides the cellular agriculture wave in alt-proteins, targeting seafood amid unsustainable wild capture (hitting breaking points) and farming, fueled by Asia's demand surge and global population growth[1][2][4]. Timing aligns with regulatory progress—FDA clearance in 2025 enables U.S. commercialization—and market forces like climate-driven stock declines, making cultivated options viable for food security[6]. It influences the ecosystem by pioneering fish (vs. land meats), educating on benefits via chef partnerships and transparency, and scaling production to alleviate ocean strain, potentially accelerating industry adoption[3][4][6].
Wildtype is poised for U.S. restaurant expansion in 2025 (e.g., daily at Kann, four more venues) and broader scaling of bioreactor capacity to meet demand, leveraging $120M+ funding for commercialization[5][6][7]. Trends like regulatory wins, Asia-focused growth, and sustainability mandates will propel it, with potential for product lines (naming system ready) amid cultivated meat's evolution[3][4]. Its influence may grow by normalizing cell-based seafood, pressuring conventional supply chains, and defending wild oceans—transforming "seafood without the sea" from niche to staple, as hinted in its mission to build a better food system[1][2].
